Woking, 08:00, Thursday September 15
McLaren Group today announces that it has formed a long-term strategic
partnership with one of the world's leading pharmaceutical corporations,
GlaxoSmithKline (GSK). This ground-breaking collaboration brings
together two great British companies, both of which are focused on
innovation and high-tech research, and will run initially to 2016.
This relationship is not a conventional business consultancy - it is
more specific, dynamic and game-changing than that. It is the
distillation, communication and application of 45 years' worth of
winning Formula 1 expertise, meticulously adapted and tailored to the
needs of a new McLaren Group partner, GSK.
The scientific elements of this expertise include analytics, data
management, strategy modelling, processes, telemetry and human IP -
elements that sit at the very heart of McLaren's unique and bespoke
technical DNA, which is characterised by a relentless and fast-paced
pursuit of ultra-accurate technological high-performance.
Specifically, GSK has selected McLaren Group as a strategic partner in
order to deliver its business a unique competitive advantage. That
advantage will manifest itself in myriad ways, including (but not
limited to):
- The development of more efficient planning processes
- The development of data modelling tools to inform strategic
decision-making
- The development of better real-time monitoring, scenario-planning and
forecasting
- The inspiration and development of GSK's managers, and the preparation
of its managers to be able to make better and more informed business
choices while remaining agile and adaptable to ever-changing
circumstances
The initial focus of the partnership will be on GSK's Manufacturing, R&D
and Consumer Healthcare businesses, and specifically its GSK
Nutritionals business unit, which markets key brands such as Lucozade,
Panadol and Sensodyne.
For example, based on McLaren Racing's existing Formula 1 race-strategy
Mission Control centre, GSK Nutritionals will construct an all-new
Mission Control facility at its London headquarters. This facility will
drive faster decision-making around variables such as wholesaler
stocking, inventory management, pricing, responding to retailer
requests, competitor activity, and market and customer needs. This
facility will reflect a perfect synthesis of the McLaren/GSK
collaboration.
McLaren-developed analytical and performance management tools and
expertise will also be used to improve GSK Nutritionals' ability to make
faster decisions around longer-term investment allocation for new
product development and innovations.
Andrew Witty, CEO, GlaxoSmithKline (GSK), said:
"I am delighted to announce this partnership with McLaren, which brings
together two British companies whose continued success hinges on the
ability to innovate and rapidly respond to change and competitor
activity.
"McLaren has an unparalleled reputation for innovation, built on
rigorous analytics and fast decision-making.
"This partnership is another example of GSK looking outside its sector
for inspiration and fresh perspectives on how we can achieve our
strategic goals in an ever more challenging and fast-changing business
environment."
Whilst the initial focus of the partnership is on Consumer Healthcare,
other business units within GSK, including R&D and manufacturing, are
also reviewing their business processes to identify areas that may
benefit.
In addition, a brand-new state-of-the-art learning facility will be
constructed as part of the agreement. It will be called the McLaren GSK
Centre for Applied Performance and will be located alongside the
existing award-winning McLaren Technology Centre in Woking, Surrey.
Employees from both organisations, and other partners, will be able to
use the facility to share ideas and collaborate on innovative, dynamic
and exciting joint working projects. The McLaren GSK Centre for Applied
Performance will be opened in 2013.
Ron Dennis, Executive Chairman, McLaren Group and McLaren Automotive,
said:
"This all-new collaboration between McLaren Group and GSK - McLaren's
first ever such association with a major pharmaceutical corporation -
represents a ground-breaking strategic partnership that engages two
great British companies at a variety of levels across a number of
disciplines in a multi-faceted and ground-breaking way.
"Specifically, our intention is that GSK will harness McLaren's
world-beating Formula 1-bred technology, processes and operational
dynamism, in order to enhance its [GSK's] performance across a wide
variety of its divisions in a way that none of its competitors can
match.
"More than that, though, this all-new partnership is a pioneering and
game-changing initiative that will play to the UK's strengths as a
globally competitive industrial powerhouse for science, engineering,
technology and R&D.
"In today's challenging economic conditions, we firmly believe that
innovative associations such as ours will play an increasingly
significant role in ensuring that the UK remains globally competitive in
the field of scientific innovation."
No comments:
Post a Comment